Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.20

-3.8%

12:07 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Sam Citron who wrote (13329)	10/6/2004 2:54:13 AM
From: Icebrg	Read Replies (1) of 52153

[CTIC] >>As I have stated before, I consider the current market as a whole to be rather uninspiring, and so I view opportunities like this, where one can make 20% in under 6 months in a stagnant stock to be quite attractive.>> Sam, the reason for the high premium is the expected release of Xyotax Stellar 3 data early next year. That will be a truly binary event. Especially on the upside. The downside seems better protected as the current valuation appears to be "supported" by Pixantrone and to certain degree also by Trisenox. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next